Physician profile
Alicia Bisplinghoff
NPI 1811758642
$2,943.75
in general payments reported to CMS, 2019-2025
24 companies · $1,889 in 2025
The $1,889 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,054 · 2025: $1,889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,943.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $467.42 | 2024-2025 | |
| Abbvie INC. | $380.69 | 2024-2025 | |
| Novo Nordisk INC | $358.41 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Esperion Therapeutics, INC. | $280.08 | 2024-2025 | Nexletol |
| Glaxosmithkline, LLC. | $219.42 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $191.21 | 2024-2025 | Evenity, Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $173.85 | 2024-2025 | |
| Lilly USA, LLC | $145.01 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Intuitive Surgical, INC. | $121.83 | 2024 | |
| Astellas Pharma US INC | $112.72 | 2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.90 | 2025 | Caplyta |
| Abbott Laboratories | $65.66 | 2024-2025 | Freestyle Libre 3 |
| Ibsa Pharma INC. | $64.36 | 2024 | Tirosint, Licart, Flector |
| Exact Sciences Corporation | $55.88 | 2024-2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $40.54 | 2024-2025 | Keveyis |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $30.98 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Astrazeneca Pharmaceuticals LP | $28.70 | 2024-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $24.50 | 2025 | |
| Boston Scientific Corporation | $23.49 | 2025 | Watchman Flx |
| Corcept Therapeutics | $21.20 | 2025 | Korlym |
| Axsome Therapeutics, INC. | $20.45 | 2025 | Auvelity |
| Alnylam Pharmaceuticals INC. | $20.13 | 2024 | Givlaari |
| Phathom Pharmaceuticals, INC. | $14.60 | 2024 | Voquezna |
| Aimmune Therapeutics, INC. | $13.72 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alicia Bisplinghoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.